← All countries · Western Pacific
81%
MCV1
2005 · Administrative (country-reported)
86.4%
DTP3
2005 · Administrative (country-reported)
92.1%
IPV complete
2024 · Administrative (country-reported)
96.0%
HepB3
2023 · Administrative (country-reported)
0
Measles cases
2024 reported
5
Pertussis (whooping cough) cases
2024 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 0%1994 · Administrative (country-reported) | 0% | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | —% · Administrative (country-reported) | — | too few points | D · poor |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 86.4%2005 · Administrative (country-reported) | 86.4% | D · poor | |
| IPV1First dose of inactivated polio vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| IPV completeInactivated polio vaccine, complete primary series | 92.1%2024 · Administrative (country-reported) | 92.1% | D · poor | |
| MCV1First dose of measles-containing vaccine | 81%2005 · Administrative (country-reported) | 81% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 93.0%2024 · Administrative (country-reported) | 93.0% | D · poor | |
| RCV1First dose of rubella-containing vaccine | 81%2005 · Administrative (country-reported) | 81% | D · poor | |
| HepB3Third dose of hepatitis B vaccine | 96.0%2023 · Administrative (country-reported) | 96.0% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | 99.1%2024 · Administrative (country-reported) | 99.1% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 81.4%2005 · Administrative (country-reported) | 81.4% | D · poor | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | —% · Administrative (country-reported) | — | too few points | D · poor |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | D · poor |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2013 · Administrative (country-reported) | 0% | D · poor | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2013 · Administrative (country-reported) | 0% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 0%2013 · Administrative (country-reported) | 0% | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Rubella all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Congenital rubella syndrome all countries · vaccine evidence | 02024 | 0per 10,000 live births | D · poor | |
| Mumps all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 52024 | 29.8per 1,000,000 total population | C · weak | |
| Diphtheria all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | D · poor | |
| Tetanus (total) all countries · vaccine evidence | 02023 | 0per 1,000,000 total population | D · poor | |
| Neonatal tetanus all countries · vaccine evidence | 02023 | 0per 1,000 live births | D · poor | |
| Polio (paralytic) all countries · vaccine evidence | 02005 | 0per 1,000,000 <15 population | no data | |
| Yellow fever all countries · vaccine evidence | 02023 | 0per 1,000,000 total population | D · poor | |
| Japanese encephalitis all countries · vaccine evidence | 02019 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02023 | 0per 1,000,000 total population | too few points | D · poor |
| Typhoid all countries · vaccine evidence | 02019 | 0per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (71 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All adults | |
| DTAPDTaP (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPDTaP (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPDTaP (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPDTaP (acellular) vaccine | 4 | M15-M18 | General/routine | |
| DTAPDTaP (acellular) vaccine | 5 | Y4-Y6 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Y19 | Adults | |
| HEPA_HEPBHepatitis A, Hepatitis B (HepA-HepB) vaccine | 1 | Y19 | Adults | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M12 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | M18 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Y19 | Adults | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Diabetics 60Y with shared clinical decision | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +W4 | Adults | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Adults | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M1-M2 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6-M18 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | M2 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M4 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 3 | M6 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 4 | M12-M15 | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y19-Y26 | Adults | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y11-Y12 | General/routine | 1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M1-M2 | Adults | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M2-M6 | General/routine | 1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 3 | +M6 | Adults | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 3 | +M6 | General/routine | 1st dose can start at age 9 yrs, 2nd dose is at M6 if 2 dose series or M2 if 3 dose series, 3rd dose is at M6 if 3 dose series |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 2 | >=M6 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 3 | M6-M18 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 4 | Y4-Y6 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Y11-Y12 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | Y16 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Y19 | Adults | at 19 years, +M1 for high risk groups/adults |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12-M15 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | +M1 | Adults | at 19 years, +M1 for high risk groups/adults |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y4-Y6 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | +M1 | Risk group(s) | at 19 years, +M1 for high risk groups/adults |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Y65 | Adults | Adults 19-64 Y |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M6 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 4 | M12-M15 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Y65 | Adults | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Y60 | Adults | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnant mothers 32-36 weeks gestational age, 50 years old who are at increased risk | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Y50 | Risk group(s) | Pregnant mothers 32-36 weeks gestational age, 50 years old who are at increased risk |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | B-M8 | Risk group(s) | Infants with increased risk for RSV and born to mothers who did not receive RSV vaccine during pregnancy, OR was born within 14 days of maternal RSV vaccination |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Y19 | Adults | Td or Tdap booster every 10 yrs, Pregnant adults and adolescent at every pregnancy 27-36 weeks gestation |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Y11 | General/routine | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Td or Tdap booster every 10 yrs, Pregnant adults and adolescent at every pregnancy 27-36 weeks gestation | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 2 | +Y10 | Adults | Td or Tdap booster every 10 yrs, Pregnant adults and adolescent at every pregnancy 27-36 weeks gestation |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y19 | Adults | Td or Tdap booster every 10 yrs |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y7 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +Y10 | Adults | Td or Tdap booster every 10 yrs |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Y50 | Adults | and at 50 years, +M6 for high risk groups/adults |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M6 | Adults | and at 50 years, +M6 for high risk groups/adults |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M6 | Risk group(s) | and at 50 years, +M6 for high risk groups/adults |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.